Monday, 17 August 2026European Markets
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Platforms Move to Shore Up Trust as Leadership Shifts and AI-Adjacent Markets Wobble
Major AI and media platforms are converging on trust and accountability measures — Anthropic's Claude adding watermarks, Spotify labeling AI artists — just as OpenAI loses special-projects lead Brad Lightcap and Meta's Zuckerberg publishes a defensive manifesto on AI's societal role. In parallel, AI-adjacent financial dynamics are surfacing real stress: Wall Street firms are paying for privileged early access to Trump's Truth Social posts for trading edge, while Trump Media itself reports a $238M loss driven by falling crypto holdings, highlighting how information asymmetry and speculative digital assets are becoming entangled with AI-era platforms.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,809
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,809 facts checked against source5,205 source documents archived
Work with this data → vianewsagency.com

ESSILORLUXOTTICA And SARTORIUS STED BIO Have A High Dividend Yield And Return On Equity In The Healthcare Sector.

Loading stream...

(vianews) - essilorluxottica (el.pa) is among this list of stock assets with the highest dividend rate and return on equity on the healthcare sector.

financial asset price forward dividend yield return on equity
essilorluxottica (el.pa) €209.70 1.92% 6.3%
sartorius sted bio (dim.pa) €264.30 0.34% 8.15%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. essilorluxottica (el.pa)

1.92% forward dividend yield and 6.3% return on equity

essilorluxottica société anonyme designs, manufactures, and distributes ophthalmic lenses, frames, and sunglasses in europe, the middle east, africa, latin america, the asia-pacific, and north america. it operates through professional solutions and direct to consumer segments. the company offers lens under the essilor, varilux, crizal, eyezen, stellest, xperio, transitions, ray-ban, oakley, barberini, kodak lens, nikon, shamir, eyexpert, iwear, humanware, and optifog brands. it also provides finishing equipment, vision performance screening, eye examination and refractions, fitting parameter measurements, and small tools and consumables under the essilor instruments brand; high-tech equipment for optical surfacing, polishing, measuring, coating, and finishing, as well as consumables, tools, and services under the satisloh brand. in addition, the company provides eyewear products under the ray-ban, oakley, persol, oliver peoples, vogue eyewear, arnette, alain mikli, costa, bliz, native, luxottica, sferoflex, bolon, molsion, dbyd, and unofficial and seen, as well as other licensed brands. in addition, the company designs, develops, markets, and maintains lens edging and mounting instruments for opticians and prescription laboratories; and optometry instruments for eyecare professionals, schools, occupational medicine centers, military, and other institutions. it wholesales its products to independent opticians, distributors, third-party e-commerce platforms, and large retail chains in the eyecare and eyewear industry; and sells directly to consumers through the network of brick and mortar retail network and its online channels. the company was formerly known as essilor international société anonyme and changed its name to essilorluxottica société anonyme in october 2018. essilorluxottica société anonyme was founded in 1849 and is headquartered in paris, france.

earnings per share

as for profitability, essilorluxottica has a trailing twelve months eps of €5.08.

pe ratio

essilorluxottica has a trailing twelve months price to earnings ratio of 41.28. meaning, the purchaser of the share is investing €41.28 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.3%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, essilorluxottica's stock is considered to be oversold (<=20).

moving average

essilorluxottica's worth is higher than its 50-day moving average of €201.15 and way higher than its 200-day moving average of €180.30.

more news about essilorluxottica.

2. sartorius sted bio (dim.pa)

0.34% forward dividend yield and 8.15% return on equity

sartorius stedim biotech s.a. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. the company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. it also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. in addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other dna/rna delivery reagents and plasmid dna. it serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. the company was incorporated in 1978 and is headquartered in aubagne, france. as of december 31, 2023, sartorius stedim biotech s.a. operates as a subsidiary of sartorius ag.

earnings per share

as for profitability, sartorius sted bio has a trailing twelve months eps of €3.36.

pe ratio

sartorius sted bio has a trailing twelve months price to earnings ratio of 78.66. meaning, the purchaser of the share is investing €78.66 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.15%.

more news about sartorius sted bio.